Effects of propofol on early phase of warm hepatic ischemia/reperfusion injury.
It is still unclear whether propofol may protect the liver against ischemia/ reperfusion injury (IRI) in vivo. The livers of male Sprague-Dawley rats were subjected to 60 minutes of partial normothermic ischemia allowing perfusion to right and caudate lobes and subsequent 45 minutes of reperfusion. Either propofol (Propofol group, n = 11, 10 mg/ kg/h) or saline (Control group, n = 11) was continuously administered. At the end of reperfusion blood and liver samples were taken to analyze malondialdehyde, hepatic injury score, palmitate oxidation rate, serum AST and ALT concentrations. The malondialdehyde concentration (micromol/g tissue, mean +/- SD) was decreased in the Propofol group (1.39 +/- 0.21, perfused lobes and 1.85 +/- 0.27, ischemic reperfused lobes) compared with Control group (1.97 +/- 0.20, perfused lobes and 2.39 +/- 0.28, ischemic reperfused lobes) (P < 0.01). Hepatic injury scores were decreased in Propofol group compared with Control group (P < 0.01), but with mild hepatic injury in both groups. There were no differences of serum AST and ALT concentrations, and palmitate oxidation rate between groups. Propofol might be effective mainly in attenuation of lipid peroxidation with only minimal hepatocellular protection during the early phase of warm hepatic IRI in vivo.